Download PDF
Open Access
CC BY-NC-ND 4.0 · J Lab Physicians 2015; 7(02): 103-107
DOI: 10.4103/0974-2727.163127
Original Article

Prevalence of Mupirocin Resistance Among Staphylococci, its Clinical Significance and Relationship to Clinical Use

Authors

  • Manohar Shoorashetty Rudresh

    Departments of Microbiology, ESIC MC and PGIMSR, Rajajinagar, Bengaluru, Karnataka, India

  • Giriyapur Siddappa Ravi

    Departments of Microbiology, ESIC MC and PGIMSR, Rajajinagar, Bengaluru, Karnataka, India

  • Aravind Motagi

    Department of ESIC MH, Indore, Madhya Pradesh, India

  • Ann Mary Alex

    Departments of Microbiology, ESIC MC and PGIMSR, Rajajinagar, Bengaluru, Karnataka, India

  • Parthasarathi Sandhya

    Departments of Microbiology, ESIC MC and PGIMSR, Rajajinagar, Bengaluru, Karnataka, India

  • Bangalore Viswanath Navaneeth

    Departments of Microbiology, ESIC MC and PGIMSR, Rajajinagar, Bengaluru, Karnataka, India

Financial support and sponsorship Nil.
Further Information
Also available at
 PDF Download Permissions and Reprints

ABSTRACT

Introduction: Mupirocin competitively inhibits bacterial isoleucyl transfer-RNA synthetase and inhibit bacterial protein synthesis. Widespread usage and over the counter availability of the drug has resulted in resistance among Staphylococcus species.

Objectives: This study aimed to determine the overall prevalence of mupirocin resistance among staphylococci. Correlate clinical significance of mupirocin resistance and its relationship to clinical use.

Methods: Consecutive, nonrepetitive, clinical isolates of Staphylococcus aureus (n = 98), and coagulase-negative staphylococci (CoNS) (n = 45) from skin and soft-tissue infections between January 2014 and June 2014 were studied. Antibiotic susceptibility testing was done according to Clinical and Laboratory Standards Institute guidelines. Low- and high-level mupirocin resistance was screened by using 5 μg and 200 μg discs respectively and confirmed by agar dilution. Annual consumption of mupirocin was studied and correlated with resistance.

Results: High-level mupirocin resistance was found in 8.2% S. aureus and 15.6% of CoNS, while low-level mupirocin resistance was found in 17% S. aureus and 8.9% CoNS. High-level mupirocin resistance was more common in methicillin-sensitive S. aureus isolates when compared with methicillin-resistant S. aureus isolates (P < 0.05). Mupirocin resistant S. epidermidis were associated with methicillin resistance and constitutive clindamycin resistance.

Conclusion: High prevalence of mupirocin resistance was found in the present study. Increased prevalence of mupirocin resistance among community-acquired staphylococci demands the judicious use of the drug in the community.

Keywords

Coagulase-negative staphylococci - methicillin resistant Staphylococcus aureus - methicillin sensitive Staphylococcus aureus - mupirocin resistance - Staphylococus aureus


Publication History

Article published online:
19 April 2020

© 2015.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • REFERENCES

  • 1 Cookson BD. The emergence of mupirocin resistance: A challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 1998;41:11-8.
  • 2 Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clin Infect Dis 2009;49:935-41.
  • 3 de Oliveira NE, Cardozo AP, Marques Ede A, dos Santos KR, Giambiagi-deMarval M. Interpretive criteria to differentiate low- and high-level mupirocin resistance in Staphylococcus aureus. J Med Microbiol 2007;56(Pt 7):937-9.
  • 4 Schmitz FJ, Lindenlauf E, Hofmann B, Fluit AC, Verhoef J, Heinz HP, et al.The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 1998;42:489-95.
  • 5 De Paulis AN, Predari SC, Chazarreta CD, Santoianni JE. Five-test simple scheme for species-level identification of clinically significant coagulase-negative staphylococci. J Clin Microbiol 2003;41:1219-24.
  • 6 Clinical and Laboratory Standards Institute (CLSI). M100-S24. Performance Standards for Antimicrobial Susceptibility Testing: 24th Informational Supplement. Wayne, PA: CLSI; 2014.
  • 7 Clinical and Laboratory Standards Institute (CLSI). M7-A9. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 9th ed. Wayne, PA: CLSI; 2012.
  • 8 Seah C, Alexander DC, Louie L, Simor A, Low DE, Longtin J, et al.MupB, a new high-level mupirocin resistance mechanism in Staphylococcus aureus. Antimicrob Agents Chemother 2012;56:1916-20.
  • 9 Bathoorn E, Hetem DJ, Alphenaar J, Kusters JG, Bonten MJ. Emergence of high-level mupirocin resistance in coagulase-negative staphylococci associated with increased short-term mupirocin use. J Clin Microbiol 2012;50:2947-50.
  • 10 Abimanyu N, Murugesan S, Krishnan P. Emergence of methicillin-resistant Staphylococcus aureus ST239 with high-level mupirocin and inducible clindamycin resistance in a tertiary care center in Chennai, South India. J Clin Microbiol 2012;50:3412-3.
  • 11 Krishnan PU, Miles K, Shetty N. Detection of methicillin and mupirocin resistance in Staphylococcus aureus isolates using conventional and molecular methods: A descriptive study from a burns unit with high prevalence of MRSA. J Clin Pathol 2002;55:745-8.
  • 12 Gadepalli R, Dhawan B, Mohanty S, Kapil A, Das BK, Chaudhry R, et al.Mupirocin resistance in Staphylococcus aureus in an Indian hospital. Diagn Microbiol Infect Dis 2007;58:125-7.
  • 13 Oommen SK, Appalaraju B, Jinsha K. Mupirocin resistance in clinical isolates of staphylococci in a tertiary care centre in South India. Indian J Med Microbiol 2010;28:372-5.
  • 14 Jayakumar S, Meerabai M, Banu SA, Mathew R, Kalyani M, Lal BY. Prevalence of high and low level mupirocin resistance among staphylococcal isolates from skin infection in a tertiary care hospital. J Clin Diagn Res 2013;7:238-42.
  • 15 Rajkumari N, Mathur P, Bhardwaj N, Gupta G, Dahiya R, Behera B, et al.Resistance pattern of mupirocin in methicillin-resistant Staphylococcus aureus in trauma patients and comparison between disc diffusion and E-test for better detection of resistance in low resource countries. J Lab Physicians 2014;6:91-5.
  • 16 Chaturvedi P, Singh AK, Singh AK, Shukla S, Agarwal L. Prevalence of mupirocin resistant Staphylococcus aureus isolates among patients admitted to a tertiary care hospital. N Am J Med Sci 2014;6:403-7.
  • 17 Hurdle JG, O'Neill AJ, Mody L, Chopra I, Bradley SF. In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. J Antimicrob Chemother 2005;56:1166-8.
  • 18 Cadilla A, David MZ, Daum RS, Boyle-Vavra S. Association of high-level mupirocin resistance and multidrug-resistant methicillin-resistant Staphylococcus aureus at an academic center in the midwestern United States. J Clin Microbiol 2011;49:95-100.
  • 19 Teo BW, Low SJ, Ding Y, Koh TH, Hsu LY. High prevalence of mupirocin-resistant staphylococci in a dialysis unit where mupirocin and chlorhexidine are routinely used for prevention of catheter-related infections. J Med Microbiol 2011;60(Pt 6):865-7.
  • 20 Simor AE, Stuart TL, Louie L, Watt C, Ofner-Agostini M, Gravel D, et al.Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 2007;51:3880-6.
  • 21 Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: A recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother 2003;51:613-7.